PETS
NASDAQPetMed Express Inc.
SectorConsumer StaplesIndustryRetail-Drug Stores and Proprietary Stores
Price$1.19-0.02 (-1.65%)
01:45 PM07:45 PM
News · 26 weeks39-14%
2026-04-262026-10-18
Mix2690d
- SEC Filings9(35%)
- Insider9(35%)
- Other3(12%)
- Leadership3(12%)
- Earnings2(8%)
Latest news
25 items- PRPetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (NASDAQ:PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment. On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units ("PSUs"), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock. The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as am
- INSIDERCEO and President Willard Jeffrey Allen was granted 250,000 shares (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- INSIDERSEC Form 3 filed by new insider Willard Jeffrey Allen3 - PETMED EXPRESS INC (0001040130) (Issuer)
- SECSEC Form S-8 filed by PetMed Express Inc.S-8 - PETMED EXPRESS INC (0001040130) (Filer)
- SECSEC Form S-8 filed by PetMed Express Inc.S-8 - PETMED EXPRESS INC (0001040130) (Filer)
- SECPetMed Express Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
- INSIDERDirector Elkeles Tamar was granted 49,923 shares (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- INSIDERSEC Form 3 filed by new insider Elkeles Tamar3 - PETMED EXPRESS INC (0001040130) (Issuer)
- SECPetMed Express Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
- PRPetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent DirectorDELRAY BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (NASDAQ:PETS), today announced the appointment of Tamar Elkeles, PhD as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026. Dr. Elkeles brings more than three decades of experience as an executive, board member, and strategic advisor across the technology, enterprise software and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she helped shape the human capital strategy that supported the company's growth from $100 million to more than $25 billio
- SECPetMed Express Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
- PRPetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership TransitionDELRAY BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (NASDAQ:PETS), today announced the appointment of consumer and e-commerce sector veteran, Jeff Willard, as Chief Executive Officer and President, as well as a member of the Board of Directors, effective September 28, 2026. Mr. Willard succeeds Leslie C.G. Campbell, who, in addition to serving as Chair of the Board of PetMeds, has served as Interim Chief Executive Officer and President since August 2025. Mr. Willard brings more than 25 years of proven leadership experience at leading consumer and e-commerce companies, with a distinguished track record of driving sustaina
- PRPetMeds Appoints Andrew Parry as Chief Technology OfficerDELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (NASDAQ:PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems. Parry brings more than three decades of technology leadership experience and joins PetMeds from The ODP Corporation, where he most recently served as Senior Vice President and Chief Information Officer, leading technology for the retail, business solutions and supply-chain units. In that role, he execu
- INSIDERInterim CEO and President Campbell Leslie C.G. was granted 60,000 shares, increasing direct ownership by 71% to 145,000 units (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- SECSEC Form 10-Q filed by PetMed Express Inc.10-Q - PETMED EXPRESS INC (0001040130) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PetMed Express Inc.SCHEDULE 13G/A - PETMED EXPRESS INC (0001040130) (Subject)
- SECPetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
- PRPetMeds® Announces First Quarter Financial ResultsDELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced its financial results for its first quarter ended June 30, 2026. Quarterly Highlights Net sales demonstrated sequential quarterly stabilization. For the first quarter ended June 30, 2026, net sales were $41.0 million compared to $51.2 million for the prior year period, a decrease of 19.9%, as lower consumer promotional usage was more than offset by a decline in prescription medication sales.Net loss for the quarter ended June 30, 2026, was $6.1 million, or $(0.28) per diluted share, compared to a net loss of $34.2 million, or $(1.65) per di
- SECPetMed Express Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
- INSIDERDirector Lacamp James was granted 55,555 shares, increasing direct ownership by 159% to 90,421 units (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- INSIDERDirector Batushansky Peter was granted 55,555 shares, increasing direct ownership by 153% to 91,928 units (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- INSIDERDirector Mennen Justin L. was granted 55,555 shares, increasing direct ownership by 130% to 98,274 units (SEC Form 4)4 - PETMED EXPRESS INC (0001040130) (Issuer)
- PRPetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026DELRAY BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) today announced it will report financial results for the first quarter fiscal year ended June 30, 2026, on Thursday, August 13, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day. Date: Thursday, August 13, 2026Time: 4:30pm Eastern Time (1:30pm Pacific Time)U.S. dial-in number: 877-407-0789International number: 201-689-8562Webcast: 1Q Earnings Webcast A telephonic replay of the conference call will also be available after 7:30 PM Eastern Time on the same day throu
- INSIDERAmendment: CAO and Interim CFO Krulik Douglas was granted 32,500 shares, increasing direct ownership by 46% to 102,500 units (SEC Form 4)4/A - PETMED EXPRESS INC (0001040130) (Issuer)
- SECPetMed Express Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PETMED EXPRESS INC (0001040130) (Filer)
PETS FAQ
6 questionsWhat does PetMed Express Inc. do?
PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain...Where does PETS stock trade?
PetMed Express Inc. (PETS) is listed on NASDAQ.What sector and industry is PETS in?
PetMed Express Inc. operates in the Consumer Staples sector, Retail-Drug Stores and Proprietary Stores industry.What are analysts saying about PETS?
PetMed Express Inc. has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $2000.00 price target on 2023-05-25. Recent price targets range from $2000.00 to $3200.00.What companies are similar to PETS?
Notable peers in the same industry include CVS (CVS Health Corporation), WBA (Walgreens Boots Alliance Inc.), GRDN (Guardian Pharmacy Services Inc.), RAD (Rite Aid Corporation), MDVL (MedAvail Holdings Inc.). Compare PETS side-by-side with any of them on Quantisnow.How can I track PETS on Quantisnow?
Quantisnow aggregates PetMed Express Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PETS to receive live email and push alerts on every new disclosure.